Volume : 11, Issue : 12, December – 2024
Title:
DEVELOPMENT AND VALIDATION METHOD FOR THE SIMULTANEOUS ESTIMATION OF EMPAGLIFLOZIN LINAGLIPTIN, AND METFORMIN IN SOLID DOSAGE FORMS BY OF RP-HPLC
Authors :
P.Prasanna Laxmi, P.Aravindra Reddy
Abstract :
The purpose of the investigation was to develop a simple, rapid and accurate RP-HPLC method to determine assay of Linagliptin, Empagliflozin and Metformin in solid dosage forms. Simultaneous Estimation of Linagliptin, Empagliflozin and Metformin were carried out by RP- HPLC using trimethylamine buffer & acetonitrile and Agilent Eclipse XDB (250 mmx 4.6mm, 5µ) as a stationary phase and peak was observed at 240 nm which was selected as a wavelength for quantitative estimation. After the development of the method, it was validated for various parameters. It was found that recovery value of pure drug was between 99 % to 101% which indicates that the method is accurate and also reveals that commonly used excipients and additives present in the pharmaceutical formulations were not interfering in the proposed methods. The ruggedness of the method was checked by different analysts and found that the results were nearly same which indicates that the method is rugged. Based on the results observed, it was concluded that proposed method can be used for routine analysis of Linagliptin, Empagliflozin and Metformin.
Keywords: RP-HPLC, Linagliptin, Empagliflozin and Metformin.
Cite This Article:
Please cite this article in press P.Aravindra Reddy et al Development And Validation Method For The Simultaneous Estimation Of Empagliflozin Linagliptin, And Metformin In Solid Dosage Forms By Of RP-HPLC.,Indo Am. J. P. Sci, 2024; 11 (12).
Number of Downloads : 10
References:
1. Chawla G, Chaudhary KK. A complete review of empagliflozin: most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(3):2001-2008.
2. Chadeve A. a review on pharmacology and therapeutic effects of Empagliflozin in patients with type 2 diabetes mellitus. asian j. pharm. clin. res. 2020;13(5):16-21.
3. Ndefo UA, Anidiobi NO, Basheer E, Eaton EA. Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes. Pharm. Ther. 2015;40(6):364-368.
4. Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 ;42(10):999- 1024.
5. Tella SH, Akturk HK, Rendell M. Linagliptin for the treatment of type 2 diabetes. Diabetes Manag. 2014;4(1):85-101.
6. Trindade MT, Kogawa AC, Salgado HR. Metformin: A Review of Characteristics, Properties, Analytical Methods and Impact in the Green Chemistry. Crit Rev Anal Chem. 2018;48(1):66-72.
7. Song R. Mechanism of metformin: A tale of two sites. Diabetes Care. 2016 ;39(2):187-9.
8. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017 ;60(9):1577-85.
9. Center for Drug Evaluation and Research [Internet]. Application number: 212614Orig1s000-Clinical Pharmacology and pharmaceutics review. Available from: 2614Orig1s000ClinPharmR.pdf. [Last accessed on 20 Aug 2020]
10. Lingvay I, Beetz N, Sennewald R, Schuler Metz A, Bertulis J, Loley C, Lang B, Lippert C, Lee J, Manning LS, Terada D. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med. 2020 May 04;132(4):337-45. doi:10.1080/00325481.2020.1750228, PMID 32366156.
11. Kar M, Choudhury PK. HPLC method for estimation of metformin hydrochloride in formulated microspheres and tablet dosage form. Indian J Pharm Sci. 2009;71(3):318-20. doi: 10.4103/0250-474X.56031, PMID 20490303.
12. Chhetri HP, Thapa P, Van Schepdael A. HPLC method for the quantification of metformin hydrochloride in bulk and dosage forms. Int J Pharm Sci Res. 2013 Jul 01;4(7):2600-4.